Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on May 26, 2026. The company is incorporated in Delaware and maintains its principal executive offices in Bothell, WA. The filing relates to a press release issued on the same date regarding the company's novel direct-acting antivirals.
Financial Metrics
This filing is a Regulation FD disclosure and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing does not report material changes to financial performance or operations compared to prior periods. The primary event is the issuance of a press release concerning the company's product pipeline.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of a press release regarding novel direct-acting antivirals. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific guidance, risks, or contingencies are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the full content of the press release (Exhibit 99.1) for details on the novel direct-acting antivirals.
- Confirm the current status of the company's clinical trials or regulatory approvals for the mentioned antivirals.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains no financial metrics.
- Note that the information disclosed is not incorporated by reference into other SEC filings.